Contineum Therapeutics, Inc. Class A Common Stock Total Liabilities
Contineum Therapeutics, Inc. Class A Common Stock total liabilities. Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has total liabilities worth $10.71 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Contineum Therapeutics, Inc. Class A Com to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Total liabilities of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Carindale Property Trust
AU:CDP
|
Australia | AU$232.30 Million |
|
Incar Financial Service Co. Ltd.
KQ:211050
|
Korea | ₩854.48 Billion |
|
cBrain A/S
CO:CBRAIN
|
Denmark | Dkr120.83 Million |
|
Metrodata Electronics Tbk
JK:MTDL
|
Indonesia | Rp8.10 Trillion |
|
Shanghai Information2 Software Inc. A
SHG:688435
|
China | CN¥125.48 Million |
|
Ever Ohms Technology Co. Ltd.
TW:6834
|
Taiwan | NT$1.06 Billion |
|
ABC arbitrage SA
PA:ABCA
|
France | €15.48 Million |
|
Zhejiang Dayang Biotech Group Co
SHE:003017
|
China | CN¥706.73 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Contineum Therapeutics, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CTNM total assets.
Liquidity & Leverage Metrics
Contineum Therapeutics, Inc. Class A Common Stock Total Liabilities Ratios Explained
Contineum Therapeutics, Inc. Class A Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 37.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Contineum Therapeutics, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total liabilities of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.65 Million | +5.90% |
| 2024-12-31 | $14.78 Million | -92.55% |
| 2023-12-31 | $198.32 Million | +1644.87% |
| 2022-12-31 | $11.37 Million | +27.28% |
| 2021-12-31 | $8.93 Million | -- |
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more